Journal of Immunotherapy

Skip Navigation LinksHome > May 2012 - Volume 35 - Issue 4 > The Role of Antigen Cross-presentation From Leukemia Blasts...
Journal of Immunotherapy:
doi: 10.1097/CJI.0b013e31824b3b14
Basic Studies

The Role of Antigen Cross-presentation From Leukemia Blasts on Immunity to the Leukemia-associated Antigen PR1

Alatrash, Gheath*; Ono, Yoko; Sergeeva, Anna*; Sukhumalchandra, Pariya*; Zhang, Mao*; St John, Lisa S.*; Yang, Tian-Hui*; Ruisaard, Kathryn*; Armistead, Paul M.; Mittendorf, Elizabeth A.§; He, Hong*; Qiao, Na§; Rodriguez-Cruz, Tania; Liang, Shoudan*; Clise-Dwyer, Karen*; Wieder, Eric D.; Lizee, Gregory; Lu, Sijie*; Molldrem, Jeffrey J.*

Supplemental Author Material
Collapse Box


Cross-presentation is an important mechanism by which exogenous tumor antigens are presented to elicit immunity. Because neutrophil elastase (NE) and proteinase-3 (P3) expression is increased in myeloid leukemia, we investigated whether NE and P3 are cross-presented by dendritic cells (DC) and B cells, and whether the NE and P3 source determines immune outcomes. We show that NE and P3 are elevated in leukemia patient serum and that levels correlate with remission status. We demonstrate cellular uptake of NE and P3 into lysosomes, ubiquitination, and proteasome processing for cross-presentation. Using anti-PR1/human leukocyte antigen-A2 monoclonal antibody, we provide direct evidence that B-cells cross-present soluble and leukemia-associated NE and P3, whereas DCs cross-present only leukemia-associated NE and P3. Cross-presentation occurred at early time points but was not associated with DC or B-cell activation, suggesting that NE and P3 cross-presentation may favor tolerance. Furthermore, we show aberrant subcellular localization of NE and P3 in leukemia blasts to compartments that share common elements of the classic major histocompatibility class I antigen-presenting pathway, which may facilitate cross-presentation. Our data demonstrate distinct mechanisms for cross-presentation of soluble and cell-associated NE and P3, which may be valuable in understanding immunity to PR1 in leukemia.

© 2012 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Call for Papers

Journal of Immunotherapy has issued a call for papers. With an impact factor of 3.203, JOI is a leading journal in the fields of immunology and oncology.

For manuscript submission, go to:

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.